# An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

> **NCT01846468** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 205 (actual)

## Conditions studied

- Chronic Renal Insufficiency

## Interventions

- **DRUG:** LHW090
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01846468
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-01
- **Primary completion:** 2014-06-28
- **Final completion:** 2014-06-28
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01846468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01846468, "An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01846468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*